替格瑞洛对心肌梗死经皮冠状动脉介入治疗患者心肌再灌注损伤的改善作用  

Improvement of Ticagrelor on Myocardial Reperfusion Injury in Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention

作　　者：凌波 张明玺[1] 李志丹[1] 

机构地区：[1]丹江口市第一医院心血管内科,湖北丹江口442700

出　　处：《中国医院用药评价与分析》2017年第9期1213-1215,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨替格瑞洛对心肌梗死经皮冠状动脉介入治疗患者心肌再灌注损伤的影响。方法:选取2015年3月—2016年7月丹江口市第一医院收治的心肌梗死拟行经皮冠状动脉介入治疗患者152例作为研究对象,以随机数字表法分为观察组和对照组,每组76例。对照组患者给予氯吡格雷联合阿司匹林治疗,观察组患者给予替格瑞洛联合阿司匹林治疗。观察两组患者不良心脏事件发生情况及治疗前后凝血功能指标水平、冠状动脉心肌梗死溶栓试验血流分级变化情况。结果:住院期间,观察组患者不良心脏事件发生率为13.16%(10/76),明显低于对照组的34.21%(26/76),差异有统计学意义(P<0.05)。治疗后,观察组患者血小板聚集率明显低于对照组,差异有统计学意义(P<0.05);两组患者血小板计数、凝血酶时间、活化凝血时间的差异无统计学意义(P>0.05)。治疗后,观察组中心肌梗死溶栓试验血流分级3级患者所占比例为36.84%(28例),明显高于对照组的15.79%(12例),差异有统计学意义(P<0.05)。结论:替格瑞洛能有效抑制心肌梗死经皮冠状动脉介入治疗患者的血小板聚集,减少心肌再灌注损伤,降低不良心脏事件发生风险。OBJECTIVE： To probe into the effect of ticagrelor on myocardial reperfusion injury in patients with myocardial infarction undergoing percutaneous coronary intervention（ PCI）. METHODS： 152 patients with myocardial infarction undergoing PCI admitted into Danjiangkou the First Hospital from Mar. 2015 to Jul. 2016 were selected and divided into observation group and control group via random number table,with 76 cases in each group. The control group was treated with clopidogrel combined with aspirin,while the observation group was given ticagrelor combined with aspirin. The incidence of adverse cardiac events,levels of coagulation indices and coronary artery thrombolysis in myocardial infarction（ TIMI） flow grades before and after treatment were observed. RESULTS： During hospital stays,the incidence of adverse cardiac events of observation group was 13. 16%（ 10/76）,which was significantly lower than that of the control group[34. 21%（ 26/76） ],with statistically significant difference（ P〈0. 05）. After treatment,the rate of platelet aggregation of observation group was significantly lower than that of the control group,with statistically significant difference（ P〈0. 05）; there were no statistical significances in differences of the platelet count,thrombin time and activated partial thromboplastin time between two groups（ P〉0. 05）. After treatment,the number of patients at the 3rd grade in TIMI flow grades of the observation group accounting for 36. 84%（ 28 cases）,which was significantly higher than that of the control group [15. 79%（ 12 cases） ],with statistically significant difference（ P〈0. 05）. CONCLUSIONS： The application of ticagrelor on patients with myocardial infarction undergoing PCI can effectively inhibit the platelet aggregation,reduce myocardial reperfusion injury and the incidence of adverse cardiac events.

关 键 词：替格瑞洛 心肌梗死 介入治疗 

分 类 号：R972[医药卫生—药品]